ANNX Stock Analysis: Buy, Sell, or Hold?
ANNX - Annexon, Inc. Common Stock
$5.21
-0.16 (-2.98%)
▼
5d:
-8.44%
30d:
-17.69%
90d:
+6.54%
HOLD
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 18, 2026
0d
Smart Money Accumulation
ANNX is down 8.4% this week, but smart money is accumulating calls. Top strike: $6 2026-07-17 with 665 OI. Call ratio: 98% View Scanner →
Strength: 9.0/10
Get Alerted When ANNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ANNX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ANNX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ANNX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ANNX is currently trading at $5.21, which is considered oversold relative to its 30-day fair value range of $5.57 to $6.20.
Technical Outlook: Technically, ANNX is showing sideways momentum. The price is currently testing key support at $5.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.12 (+151.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ANNX is showing sideways momentum. The price is currently testing key support at $5.06. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.12 (+151.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.57 -
$6.20
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 151.9% below Wall St target ($13.12)
- CAUTION: Recommendation downgraded due to -8.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$5.57 -
$6.20
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.06
Resistance Level
$6.03
Current Trend
Sideways
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.80
Wall Street Target
$13.13
(+151.9%)
Share & Embed Analysis
Last updated: May 18, 2026 7:46 AM ET
Data refreshes hourly during market hours. Next update: 8:46 AM
Data refreshes hourly during market hours. Next update: 8:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANNX showing a specific setup today?
Insider Activity (6 Months)
7
Buys
5
Sells
+
Net
INSIDERS BUYING
Recent Transactions
William H Carson
BUY
8000 shares
2026-04-10
William H Carson
BUY
8000 shares
2026-03-10
Dean Richard Artis
SELL
5290 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 55 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$203 | 52 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
